A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-22

Study Completion Date

2023-10-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single center randomized parallel-group partially-blinded, 4-arm Phase 1 study to evaluate the phototoxic potential of two dose levels of SAR441566 treatment compared to placebo and the active comparator, ciprofloxacin, in healthy adults, 18 to 55 years of age.

There will be two parts:

* Part I is a randomized placebo-controlled trial comparing sensitivity to ultraviolet (UV) light in participants treated with SAR441566 to those treated with placebo.
* Part II is an open label arm consisting of participants treated with ciprofloxacin which induces mild phototoxicity and serves as a positive control.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.

NCT05858788

Rheumatoid Arthritis

COMPLETED PHASE1

A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis

NCT06073093

Rheumatoid Arthritis

COMPLETED PHASE2

To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis

NCT02534896

Active Rheumatoid Arthritis

TERMINATED PHASE3

Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients

NCT01061736

Rheumatoid Arthritis

COMPLETED PHASE2/PHASE3

Sarilumab Effect on the Pharmacokinetics of Simvastatin

NCT02017639

Rheumatoid Arthritis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The overall duration of the study for each participant will be up to approximately 48 days

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Applicable for Part I

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part I SAR441566 Dose A

Participants will receive repeated low dose of SAR441566 for 7.5 days

Group Type EXPERIMENTAL

SAR441566

Intervention Type DRUG

Tablet

Part I SAR441566 Dose B

Participants will receive repeated high dose of SAR441566 for 7.5 days

Group Type EXPERIMENTAL

SAR441566

Intervention Type DRUG

Tablet

Part I Placebo

Participants will receive repeated SAR441566 matching placebo tablets for 7.5 days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Tablet

Part II Ciprofloxacin

Participants will receive repeated ciprofloxacin 500 mg twice-daily (BID) for 5.5 days

Group Type ACTIVE_COMPARATOR

Ciprofloxacin

Intervention Type DRUG

Tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SAR441566

Tablet

Intervention Type DRUG

Placebo

Tablet

Intervention Type DRUG

Ciprofloxacin

Tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female participants who are between 18 and 55 years of age, (inclusive), at the time of signing the informed consent
* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECG.
* Participants with Fitzpatrick skin type classification of I, II, or III (I always burns easily, never tans, II always burns easily, tans minimally, III Burns moderately, tans gradually)
* Body weight within 50.0 and 100.0 kg (inclusive), and body mass index (BMI) within the range 18.0 and 32.0 kg/m2 (inclusive)

Exclusion Criteria

* A positive hepatitis B (HBsAg, anti-HBc), hepatitis C or HIV test at screening, indicative of a current or past infection
* A history of active tuberculosis (TB) or positive serological test for TB (Quantiferon TB Gold or T-SPOT)
* History of invasive opportunistic infections
* Participants with a history of Clostridium difficile-associated diarrhea
* Participants with a history of malignancy occurring within 5 years before inclusion (except adequately treated carcinoma in situ of the cervix, or adequately treated non-metastatic squamous cell or basal cell carcinoma of the skin)
* Active skin disorders or alterations such as tattoos on the back where photosensitivity testing will be performed or unprotected ultraviolet exposure of the test areas within 4 weeks prior to baseline photo testing that the Investigator considers will interfere with study assessments
* Abnormal skin response during preliminary or baseline phototoxicity evaluations
* Any medication within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication (whichever is longer); any acetaminophen intake within 2 days prior the inclusion and any biologics (antibody or its derivatives) given within 4 months before screening
* Any participant enrolled or having participated, in this or any other clinical study involving an IMP or in any other type of medical research within the past 14 days (last day of IMP dosing in the previous clinical trial) or 5 half-lives whichever is longer, before screening
* Clinical signs and symptoms consistent with COVID-19 or laboratory-confirmed SARS-CoV-2 infection; SARS-CoV-2 infection within 4 weeks prior to screening; and/or history of severe course of COVID-19
* If female, pregnancy (defined as positive beta-HCG blood test and/or positive urine pregnancy test), breast-feeding

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes